NASDAQ:CERS - Cerus Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.24
▼ -0.08 (-1.27%)

This chart shows the closing price for CERS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cerus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cerus in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.24.

This chart shows the closing price for CERS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Cerus. This rating has held steady since May 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$9.00High
6/8/2020Cantor FitzgeraldReiterated RatingOverweightHigh
5/27/2020Stifel NicolausBoost Price TargetBuy$7.00 ➝ $8.00Low
4/16/2020StephensLower Price TargetOverweight$7.50 ➝ $6.50Low
2/26/2020BTIG ResearchInitiated CoverageBuy$7.00High
11/13/2019BTIG ResearchUpgradeNeutral ➝ Buy$7.00Medium
8/27/2019Stifel NicolausInitiated CoverageBuy$7.00 ➝ $7.00Medium
8/22/2019StephensInitiated CoverageOverweight$8.00High
12/18/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
12/10/2018Cantor FitzgeraldReiterated RatingBuy$9.00Low
10/3/2018Cantor FitzgeraldReiterated RatingBuy$9.00Low
8/3/2018CowenSet Price TargetBuy$10.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
7/20/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Reduce$9.00Medium
5/9/2018BTIG ResearchReiterated RatingHoldHigh
3/10/2018BTIG ResearchReiterated RatingHoldMedium
1/25/2018BTIG ResearchReiterated RatingHoldLow
1/23/2018Cantor FitzgeraldReiterated RatingBuy$5.00High
1/8/2018Cantor FitzgeraldSet Price TargetBuy$5.00Low
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00Medium
12/8/2017BTIG ResearchReiterated RatingNeutral ➝ NeutralLow
12/1/2017Robert W. BairdReiterated RatingBuy$5.00Low
10/5/2017CowenSet Price TargetBuy$6.00N/A
6/7/2017Cantor FitzgeraldReiterated RatingBuy$7.00High
5/28/2017BTIG ResearchReiterated RatingBuy$5.00Low
5/23/2017Cantor FitzgeraldSet Price TargetBuy$7.00High
5/4/2017Cantor FitzgeraldSet Price TargetBuy$9.00High
4/17/2017CowenLower Price TargetOutperform$9.50 ➝ $7.00Low
3/10/2017BTIG ResearchReiterated RatingBuy$8.00N/A
3/8/2017FBR & Co.Set Price TargetBuy$10.00Low
3/8/2017Cantor FitzgeraldReiterated RatingOverweight$9.00High
2/23/2017BTIG ResearchReiterated RatingBuy$8.00N/A
12/22/2016FBR & Co.Reiterated RatingOutperform$10.00N/A
11/7/2016FBR & Co.Reiterated RatingBuy$10.00N/A
11/6/2016Cantor FitzgeraldSet Price TargetBuy$9.00N/A
10/27/2016BTIG ResearchReiterated RatingBuy$10.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 4 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2021

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Cerus logo
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Read More

Today's Range

Now: $6.24
Low: $6.18
High: $6.29

50 Day Range

MA: $6.20
Low: $5.69
High: $6.68

52 Week Range

Now: $6.24
Low: $4.67
High: $8.87

Volume

397,901 shs

Average Volume

1,706,253 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Cerus?

The following Wall Street analysts have issued research reports on Cerus in the last year: Zacks Investment Research.
View the latest analyst ratings for CERS.

What is the current price target for Cerus?

0 Wall Street analysts have set twelve-month price targets for Cerus in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cerus in the next year.
View the latest price targets for CERS.

What is the current consensus analyst rating for Cerus?

Cerus currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CERS.

How do I contact Cerus' investor relations team?

Cerus' physical mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company's listed phone number is (925) 288-6000 and its investor relations email address is [email protected] The official website for Cerus is www.cerus.com.